CEACAM5 and lung adenocarcinoma: Similarly, there was no difference between serum-CEA in patients with primary lung adenocarcinoma, 3.3 (0.4-15.7) ng∙mL−1, and that in the control group, 1.8 (0.6-9.1) ng∙mL−1, (P = 0.056).